Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial

Published:2016-10-21 Issue:6 Volume:78 Page:1175-1184
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Krischke Miriam,Hempel Georg,Völler Swantje,André Nicolas,D’Incalci Maurizio,Bisogno Gianni,Köpcke Wolfgang,Borowski Matthias,Herold Ralf,Boddy Alan V.,Boos Joachim

Funder

Directorate-General for Research and Innovation

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-016-3174-8.pdf

Reference19 articles.

1. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324(12):808–815. doi: 10.1056/NEJM199103213241205

2. Franco VI, Henkel JM, Miller TL, Lipshultz SE (2011) Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol Res Pract 2011:134679. doi: 10.4061/2011/134679

3. Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dube MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR, Canadian Pharmacogenomics Network for Drug Safety C (2012) Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 30(13):1422–1428. doi: 10.1200/JCO.2010.34.3467